IP Library Granted Patent US 12,708,631
Granted Patent B2
US 12,708,631 · App. 17/429,259 · Granted Aug 18, 2026

Compositions comprising cannabinoids and methods of use thereof

Inventor: George D. Pappas (Oak Park, IL)
Assignee: Schedule 1 Therapeutics, Inc.
A61K31/658A61K45/06A61P25/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,708,631
App. No.
17/429,259
Granted
Aug 18, 2026
Kind
B2
Abstract

The present disclosure is related to the use of compositions and their use in reducing pain.

Claims (8)

1 . A method of reducing acute migraine pain, photophobia, phonophobia, nausea, or frequency in a subject, the method comprising administering a pharmaceutically effective amount of at least one minor cannabinoid in combination with THC and CBD such that at least one biomarker of central and peripheral sensitization is modulated and acute migraine pain, photophobia, phonophobia, nausea, or frequency is reduced in the subject, wherein the composition comprises 80 w/w % CBD to 99.9 w/w % CBD and 0.1 w/w % THC to 20 w/w % THC wherein the biomarker is selected from the group consisting of NMDA, glutamate, CGRP, FAAH, Substance P, NO, GABA, NGF, serotonin, dopamine, AEA, and 2-AG.

2 . The method of claim 1 , wherein the subject has chronic migraines.

3 . The method of claim 1 , wherein the subject suffers from high frequency migraine.

4 . The method of claim 1 , wherein the minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

5 . The method of claim 1 , wherein the composition comprises 0.1 w/w % to 0.5 w/w % THC.

6 . The method of claim 1 , wherein the composition comprises 10 w/w % THC.

7 . The method of claim 5 , wherein the composition comprises 80 w/w % to 95 w/w % CBD.

8 . A method of reducing acute migraine pain, photophobia, phonophobia, nausea, or frequency in a subject, the method comprising administering a pharmaceutically effective amount of at least one minor cannabinoid in combination with THC and CBD such that at least one biomarker of central and peripheral sensitization is modulated and acute migraine pain, photophobia, phonophobia, nausea, or frequency is reduced in the subject, wherein the composition comprises at least 90 w/w % CBD and no more than 10 w/w % THC wherein the biomarker is selected from the group consisting of NMDA, glutamate, CGRP, FAAH, Substance P, NO, GABA, NGF, serotonin, dopamine, AEA, and 2-AG.